Evidence Grade A — Regulatory approved. 3723 published studies. 6 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Gramicidin is a topical antibiotic peptide found in combination eye drops such as Neosporin Ophthalmic Solution. It is far too toxic for systemic use but provides effective gram-positive bacterial coverage when applied directly to the eye surface. Historically, gramicidin is significant as one of the very first antibiotics ever discovered — its success in animals in 1939 was a key catalyst for the development of penicillin.
Gramicidin is also known by these brand and alternate names:
3,723 published studies: 517 human, 780 animal, 227 in-vitro, 147 reviews
Gramicidin is available in combination ophthalmic products such as Neosporin Ophthalmic Solution (with neomycin and polymyxin B), approved 1949. It provides gram-positive bacterial coverage in these combinations.
Gramicidin's significance extends well beyond its clinical use. It was the first antibiotic shown to cure systemic bacterial infections in animals (1939), and the demonstration that a natural substance could fight infection in living organisms was a key catalyst for the development of penicillin. In basic science, gramicidin remains the most-studied ion channel peptide, providing foundational understanding of how molecules transport ions across membranes.
Gramicidin has an extraordinary molecular mechanism that has made it one of the most studied peptides in biophysics. Its alternating D- and L-amino acids allow it to form a helix that spans the bacterial cell membrane. Two gramicidin molecules meet head-to-head inside the membrane, creating a tiny channel that allows ions to flood through uncontrollably — approximately six million ions per second. This destroys the bacterium's ability to maintain its internal chemistry, killing the cell. The channel is too toxic for systemic use but effective when applied topically.
Gramicidin's clinical evidence is entirely historical, predating modern trial standards by decades. Its safety and effectiveness as a topical ophthalmic antibiotic are supported by prolonged clinical experience rather than randomised controlled trials. The haemolytic (blood cell-destroying) activity that makes it unsuitable for systemic use is well documented. Outside clinical use, gramicidin is one of the most studied molecules in biophysics — the tiny ion channels it forms in cell membranes have been the subject of over 50 years of fundamental research. More recently, gramicidin's ability to accumulate in mitochondria and disrupt energy production has attracted interest in anticancer research, with laboratory screening of thousands of gramicidin variants aimed at reducing toxicity while retaining anti-tumour activity.
PeptideTrace tracks 6 registered clinical trials for Gramicidin sourced from ClinicalTrials.gov.
Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers
Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers
Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges
Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients
Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 3
Health Canada Market Authorisation
FDA SUPPL 4
FDA SUPPL 5
FDA SUPPL 6
FDA SUPPL 7
FDA SUPPL 9
FDA SUPPL 8
FDA SUPPL 10
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 14
FDA SUPPL 13
Gramicidin D is a heterogeneous mixture of linear pentadecapeptides (15 AA): gramicidin A (~80%), B (~6%), C (~14%), from Brevibacillus brevis. MW ~1,882 Da. Strictly alternating D/L-amino acids, N-terminal formyl group, C-terminal ethanolamine, four tryptophans. Extremely hydrophobic (6 mg/L solubility). First commercially manufactured antibiotic (1939). Never used systemically (hemolytic). Ophthalmic 0.025 mg/mL q4h.
In lipid bilayers, each monomer adopts right-handed beta-6.3-helix. Two monomers dimerize head-to-head (N-to-N) via six H-bonds, spanning full membrane (~25-30 A) to form an ion channel (~4 A pore). Selective for monovalent cations (H+, Na+, K+), transporting ~6.3x10^6 ions/sec. Uncontrolled Na+ influx and K+ efflux collapse electrochemical gradient, causing depolarization and lysis.
Discovered 1939, FDA approved 1949. Available only in combination ophthalmic products: Neosporin Ophthalmic Solution (neomycin + polymyxin B + gramicidin). Contributes gram-positive coverage. Indication: superficial ocular infections, exclusively as combination product component. Historically catalyzed penicillin development for systemic use in the 1940s.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion. A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Evidence Reviews
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
